Halozyme, Inc. (HALO)

Oncology Corporate Profile

Stock Performance

13.4900
0.2000

HQ Location

11388 Sorrento Valley Road
San Diego, CA 92121

Company Description

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. 

Website: http://www.halozyme.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PEGPH20 (+ ABRAXANE? + Gemcitabine)pegylated recombinant human hyaluronidasePancreatic cancerIII
PEGPH20pegylated recombinant human hyaluronidasePancreatic cancerII
PEGPH20 (+ eribulin)pegylated recombinant human hyaluronidaseBreast cancerIEisai
PEGPH20pegylated recombinant human hyaluronidaseNon Small Cell Lung Cancer (NSCLC)I
PEGPH20pegylated recombinant human hyaluronidaseVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.halozyme.com

Recent News Headlines

Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results

2/28/2017 09:00 pm

[PR Newswire] - SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and ...

Halozyme Therapeutics To Present At Upcoming Healthcare Conferences

2/23/2017 09:03 pm

[PR Newswire] - SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Cowen & Company ...

MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20

2/13/2017 01:03 pm

[PR Newswire] - SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical stage immuno-oncology drug development company, today announced results from a pre-clinical study evaluating the potential benefits of using MabVax's HuMab-5B1antibody, MVT-5873, currently in Phase I clinical trials for the treatment of metastatic pancreatic cancer with Halozyme Therapeutic's (HALO) investigational drug PEGPH20, which targets the tumor microenvironment potentially allowing increased access of co-administered cancer drug therapies to solid tumors. PEGPH20 is currently in phase III clinical development for metastatic pancreatic cancer and in phase I clinical trials for non-small cell lung cancer, gastric cancer, and metastatic breast cancer. Results from the preclinical study were positive demonstrating improvement in accumulation of MVT-5873 on tumors in an animal model of pancreatic cancer when administered in sequence with PEGPH20.

Halozyme To Host Fourth Quarter 2016 Financial Results Conference Call

2/1/2017 09:03 pm

[PR Newswire] - SAN DIEGO, Feb. 1, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...